Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia. [electronic resource]
Producer: 20070105Description: 7435-43 p. digitalISSN:- 0022-1767
- Administration, Oral
- Adult
- Aged
- Antibodies, Monoclonal -- administration & dosage
- Antibodies, Monoclonal, Murine-Derived
- Antigens, CD20 -- blood
- Antineoplastic Agents -- administration & dosage
- Complement C3 -- metabolism
- Dose-Response Relationship, Immunologic
- Drug Administration Schedule
- Drug Delivery Systems
- Female
- Humans
- Infusions, Intravenous
- Leukemia, Lymphocytic, Chronic, B-Cell -- blood
- Lymphocyte Count
- Lymphocyte Depletion
- Male
- Middle Aged
- Rituximab
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.